Effective January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred status for Commercial and Exchange Market formularies.
APPLICABLE ONLY FOR THE FOLLOWING PLANS: Blue Cross and Blue Shield of Alabama, Blue Cross and Blue Shield of Kansas, Blue Cross Blue Shield of Wyoming, Blue Cross Blue Shield North Dakota, Blue Cross and Blue Shield of Nebraska, and Florida Blue.
Please download the PDF file listed below for details.